Literature DB >> 21729240

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents.

M Levi1, E Eerenberg, P W Kamphuisen.   

Abstract

The most important adverse effect of antithrombotic treatment is the occurrence of bleeding. In the case of severe bleeding in a patient who uses anticoagulant agents or when a patient on anticoagulants needs to undergo an urgent invasive procedure, it may be useful to reverse anticoagulant treatment. Conventional anticoagulants such as vitamin K antagonists may be neutralized by administration of vitamin K or prothrombin complex concentrates, whereas heparin and heparin derivatives can be counteracted by protamine sulphate. The anti-hemostatic effect of aspirin and other antiplatelet strategies can be corrected by the administration of platelet concentrate and/or desmopressin, if needed. Recently, a new generation of anticoagulants with a greater specificity towards activated coagulation factors as well as new antiplatelet agents have been introduced and these drugs show promising results in clinical studies. A limitation of these new agents may be the lack of an appropriate strategy to reverse the effect if a bleeding event occurs, although experimental studies show hopeful results for some of these agents.
© 2011 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21729240     DOI: 10.1111/j.1538-7836.2011.04432.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  27 in total

Review 1.  Steps to consider in the approach and management of critically ill patient with spontaneous intracerebral hemorrhage.

Authors:  Daniel Agustin Godoy; Gustavo Rene Piñero; Patricia Koller; Luca Masotti; Mario Di Napoli
Journal:  World J Crit Care Med       Date:  2015-08-04

2.  Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults.

Authors:  Stefania Vaglio; Domenico Prisco; Gianni Biancofiore; Daniela Rafanelli; Paola Antonioli; Michele Lisanti; Lorenzo Andreani; Leonardo Basso; Claudio Velati; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2015-12-15       Impact factor: 3.443

Review 3.  New oral anticoagulants in non-valvular atrial fibrillation.

Authors:  Pietro Francia; Carmen Adduci; Daria Santini; Beatrice Musumeci; Giuliano Tocci
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-05-08

4.  Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation.

Authors:  Kristin M Bompiani; Jens L Lohrmann; George A Pitoc; James W Frederiksen; George B Mackensen; Bruce A Sullenger
Journal:  Chem Biol       Date:  2014-07-24

5.  Facile chemoenzymatic synthesis of biotinylated heparosan hexasaccharide.

Authors:  Baolin Wu; Na Wei; Vireak Thon; Mohui Wei; Zaikuan Yu; Yongmei Xu; Xi Chen; Jian Liu; Peng George Wang; Tiehai Li
Journal:  Org Biomol Chem       Date:  2015-05-14       Impact factor: 3.876

Review 6.  Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach.

Authors:  Marco P Donadini; Walter Ageno; James D Douketis
Journal:  Drugs       Date:  2012-10-22       Impact factor: 9.546

Review 7.  Protein engineering: a new frontier for biological therapeutics.

Authors:  Peter H Tobin; David H Richards; Randolph A Callender; Corey J Wilson
Journal:  Curr Drug Metab       Date:  2014       Impact factor: 3.731

Review 8.  New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures.

Authors:  Sergio Coccheri; Donatella Orlando
Journal:  Intern Emerg Med       Date:  2012-12-18       Impact factor: 3.397

9.  Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin.

Authors:  A Y Mehta; B M Mohammed; E J Martin; D F Brophy; D Gailani; U R Desai
Journal:  J Thromb Haemost       Date:  2016-02-16       Impact factor: 5.824

Review 10.  Direct Oral Anticoagulants in Emergency Trauma Admissions.

Authors:  Marc Maegele; Oliver Grottke; Herbert Schöchl; Oliver A Sakowitz; Michael Spannagl; Jürgen Koscielny
Journal:  Dtsch Arztebl Int       Date:  2016-09-05       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.